标题:Therapeutic effects of thalidomide in hematologic disorders: A review
作者:Xu M.; Hou Y.; Sheng L.; Peng J.
作者机构:[Xu, M] Department of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China;[ Hou, Y] Shandong University School of Medicine, Jinan, Sh 更多
通讯作者:Peng, J(junpeng88@sina.com.cn)
通讯作者地址:[Peng, J] Department of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China;
来源:Frontiers of Medicine in China
出版年:2013
卷:7
期:3
页码:290-300
DOI:10.1007/s11684-013-0277-z
关键词:lymphoma; multiple myeloma; thalidomide
摘要:The extensive autoimmune, anti-inflammatory, and anticancer applications of thalidomide have inspired a growing number of studies and clinical trials. As an inexpensive agent with relatively low toxicity, thalidomide is regarded as a promising therapeutic candidate, especially for malignant diseases. We review its therapeutic effects in hematology, including those on multiple myeloma, Waldenstroem macroglobulinemia, lymphoma, mantle-cell lymphoma, myelodysplastic syndrome, hereditary hemorrhagic telangiectasia, and graftversus-host disease. Most studies have shown satisfactory results, although several have reported the opposite. Aside from optimal outcomes, the toxicities and adverse effects of thalidomide should also be examined. The current work includes a discussion of the mechanisms through which the novel biological effects of thalidomide occur, although more studies should be devoted to this aspect. With appropriate safeguards, thalidomide may benefit patients suffering from a broad variety of disorders, particularly refractory and resistant diseases. © 2013 Higher Education Press and Springer-Verlag Berlin Heidelberg.
收录类别:SCOPUS
Scopus被引频次:5
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883453079&doi=10.1007%2fs11684-013-0277-z&partnerID=40&md5=af1f9a772555a1356bb8ffce32f18ee0
TOP